Related Experiment Video

Updated: Oct 12, 2025

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung
09:26

Antibiotic Efficacy Testing in an Ex vivo Model of Pseudomonas aeruginosa and Staphylococcus aureus Biofilms in the Cystic Fibrosis Lung

Published on: January 22, 2021

7.2K

Evaluation of Empirical Meropenem Bolus Protocol in Pseudomonas aeruginosa: A Three-Year Analysis in Tertiary

I Wayan Suranadi1, Putu Agus Surya Panji1, Ni Nyoman Sri Budayanti2

  • 1Department of Anesthesiology and Intensive Care, Faculty of Medicine, Universitas Udayana/Sanglah General Hospital, Denpasar, Bali, 80113, Indonesia.

International Journal of General Medicine
|November 19, 2021
PubMed
Abstract

Insights

The study found that the empirical meropenem administration protocol increased nonsusceptibility in Pseudomonas aeruginosa. Modifying empirical therapeutic strategies is crucial for combating antimicrobial resistance.

Area of Science:

  • Infectious Diseases
  • Clinical Pharmacy
  • Microbiology

Background:

  • Antimicrobial resistance is a growing global health concern.
  • Pseudomonas aeruginosa is a common cause of hospital-acquired infections, particularly in intensive care units.
  • Meropenem is a critical antibiotic for treating P. aeruginosa infections.

Purpose of the Study:

  • To investigate the empirical use of meropenem.
  • To analyze the susceptibility trends of P. aeruginosa to meropenem.
  • To identify factors associated with acquired nonsusceptibility in P. aeruginosa within an intensive care unit setting.

Main Methods:

  • A retrospective study was conducted in an Indonesian tertiary care hospital's intensive and high care unit.
  • Data from January 2018 to January 2021 included patients with culture-confirmed P. aeruginosa infections.
  • Hospital electronic medical records and microorganism susceptibility reports were analyzed.

Main Results:

  • An increasing trend in meropenem nonsusceptibility and multidrug-resistance rates was observed.
  • Nonsusceptibility to meropenem was acquired in 37% of patients, with most receiving empirical therapy.
  • The evaluated empirical meropenem administration protocol was a significant risk factor for P. aeruginosa nonsusceptibility (PR = 30.65; p <0.001).

Conclusions:

  • The empirical meropenem administration protocol independently contributed to the acquisition of nonsusceptibility in P. aeruginosa.
  • Modifications to empirical therapeutic strategies are essential.
  • Routine evaluation of antimicrobial use practices should be implemented to mitigate resistance.
Keywords:
IndonesiaPseudomonas aeruginosaantibiotic resistancecritical careempirical therapymeropenem

More Related Videos

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis07:16

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Published on: September 20, 2024

1.3K
A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.8K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
70
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
495
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
523
Antimicrobial Effectiveness01:28

Antimicrobial Effectiveness

The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
386
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations01:15

Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations

Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
16